Heparin Market By Product (Unfragmented Heparin, Low Molecular Weight Heparin and Ultra-Low Molecular Weight Heparin), By Route of Administration (Subcutaneous and Intravenous) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

The International Society on Thrombosis and Hemostasis 2017 report has stated the global incidence rate of venous thromboembolism to be 2 per 1000 persons. The risk factors associated with venous thromboembolism are prolonged hospital stays, cancer chemotherapy, smoking, alcohol consumption, and pregnancy. Heparin has excellent plasma protein binding properties. It has been found to be effective in the treatment of Parkinson's disease via cathepsin-D activity. Heparin, being a glycosaminoglycan, has been found to reduce inflammation in rheumatoid arthritis and acute pancreatitis.

The report titled "Heparin Market" covers product segments, including unfragmented heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The routes of administration are subcutaneous and intravenous. Data forecasting and market estimation are covered to understand the latest trend in the products and route of administration segments. 

Market size and data forecasts are covered in the geography segment to understand the attractive investment proposition by geography.

Company profiles cover important information such as recent news coverage, business information, and product portfolios. The product portfolio gives a clear understanding of the recent trend present in the heparin market. Recent news covers the latest launch of a value-added heparin product and technological developments in the production of synthetic heparin. Market Assessment and data forecasts elucidate the existing business milieu in the global heparin market. The ace players involved in the production of heparin are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy's Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on product, the global heparin market is categorized into:

  • Unfractionated Heparin
  • Heparin with a Low Molecular Weight
  • Ultra-Low Molecular Weight Heparin

Heparin is an anticoagulant prescribed for the treatment of venous complications such as arterial thromboembolism, deep vein thrombosis, and pulmonary embolism. It is produced by the mast cells and basophils and binds to the enzyme antithrombin III, which further causes the inactivation of the blood clotting factor thrombin. Heparin is produced from the mucosal tissues of slaughtered porcine and bovine animals. It is present in the World Health Organization's list of essential medicines, which demonstrates its importance in treatment. The low molecular weight represents the largest market share in the product segment due to its enhanced bioavailability and lower subcutaneous dosing frequency for complications like venous thromboembolism.

Additionally, the most important advantage of low molecular weight heparin is the reduced risk of heparin-induced thrombocytopenia. On the other hand, ultra-low molecular weight heparin has enhanced safety and efficacy due to its structural configuration, which promotes depolymerization. The medicinal application of ultra-low molecular weight heparin is being driven by rising demand as a therapeutic agent providing thromboprophylaxis in cancer patients undergoing surgery. Top players in the heparin market are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy's Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on the route of administration, the heparin market is categorized into:

  • Subcutaneous
  • Intravenous

The biological half-life of fragmented heparin is 1-2 hours after infusion, and low molecular weight heparin has a half-life four times longer than that of fragmented heparin. Proper caution needs to be taken while considering the dose specifications of heparin, as there are severe side effects of overdosing. Protamine sulfate has been useful to a certain extent in reversing the heparin overdose effect, but logically it is not possible to determine the blood concentration of heparin owing to its excellent plasma protein binding. The subcutaneous route is the most preferred route owing to its enhanced safety, shorter administration time, and relatively lower cost. It is useful in pregnant women, who have an increased risk for venous thromboembolism, and in patients undergoing reproductive immunology treatment. The intravenous route has advantages such as a quick onset of action and is the preferred route of choice in open heart surgeries, kidney dialysis, and blood transfusion.

For the purpose of this study, the global heparin market is categorized into the following regional and country-specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The National Center on Birth Defects and Developmental Disabilities has cited that every year in the United States, around 900,000 people suffer from venous thromboembolism (DVT or PE with a prevalence of 1 to 2 per 1,000 people. Approximately 10% to 30% of citizens die within a month of diagnosis, and venous thromboembolism is the leading cause of death in approximately 25% of DVT or PE patients. North America owns the largest market share in heparin products due to the increasing number of patients suffering from DVT and PE and the presence of top players actively engaged in the research and development of heparin products.

According to European Union statistics, the rising prevalence of coagulation disorders results in the death of approximately half a million EU citizens each year. Furthermore, the European Medical Agency's supportive regulatory environment for synthetic heparin products propels the European heparin market's growth. The patent expiration of low molecular weight heparin will boost the generic market in the Asia Pacific, resulting in a significant increase in heparin products. The World Health Organization has stated that the major cause of death in Asia and the Pacific regarding clotting disorders is pulmonary embolism.

Frequently Asked Questions:

The market for Heparin Market is expected to reach US$ 14,853.1 Mn by 2025.

The Heparin Market is expected to see significant CAGR growth over the coming years, at 7.21%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy's Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Jan 2018
Category:  Pharmaceuticals
Report ID:   58943
Report Format:   PDF
Pages:   120
Rating:    4.4 (25)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support